PE20091678A1 - Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion-176 - Google Patents
Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion-176Info
- Publication number
- PE20091678A1 PE20091678A1 PE2009000326A PE2009000326A PE20091678A1 PE 20091678 A1 PE20091678 A1 PE 20091678A1 PE 2009000326 A PE2009000326 A PE 2009000326A PE 2009000326 A PE2009000326 A PE 2009000326A PE 20091678 A1 PE20091678 A1 PE 20091678A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- treatment
- agonists
- compositions
- methods
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 2
- MGSBFWIIFWQXSG-UHFFFAOYSA-N 6-fluorospiro[1h-indole-3,1'-cyclopropane]-2-one Chemical compound C=1C(F)=CC=C2C=1NC(=O)C21CC1 MGSBFWIIFWQXSG-UHFFFAOYSA-N 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
REFERIDO A UN COMPUESTO DE FORMULA (I), DONDE X ES DE PREFERENCIA CH2, NH, -O-, -S-; R1 ES H, HALO, -CN, ENTRE OTROS; R2 ES -C(=O)ORa Y -C(=O)NRcRd; R3 ES ALQUILO C1-C6, HALOALQUILO C1-C6; R4 Y R5 SON CADA UNO HALO, ALQUILO C1-C6, HALOALQUILO C1-C6, ENTRE OTROS; Ra ES ALQUILO C1-C7, HALOALQUILO C1-C7, ALQUENILO C2-C6, ENTRE OTROS; Rc Y Rd SON CADA UNO H, ALQUILO C1-C7, ALQUENILO C2-C6, ENTRE OTROS; n ES 0-4; m ES 0-8; p ES 0-6. SON COMPUESTOS SELECCIONADOS: 3-METIL-3-(4-(2-OXO-2,3-DIHIDRO-1H-BENZO[D]IMIDAZOL-1-IL)PIPERIDIN-1-IL)PIRROLIDINA-1-CARBOXILATO DE ETILO; 3-(4-(4-TERC-BUTIL-6-METIL-2-OXOINDOLIN-1-IL)PIPERIDIN-1-IL)-3-METILPIRROLIDINA-1-CARBOXILATO DE METILO; 3-(4-(6'-FLUORO-2'-OXOSPIRO[CICLOPROPANO-1,3'-INDOLINA]-1'-IL)PIPERIDIN-1-IL)-3-METILPIRROLIDINA-1-CARBOXILATO DE ETILO; ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO DE PREPARACION. DICHO COMPUESTO ES AGONISTA DE LOS RECEPTORES MUSCARINICOS, SIENDO UTIL EN EL TRATAMIENTO DEL DOLOR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3308208P | 2008-03-03 | 2008-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091678A1 true PE20091678A1 (es) | 2009-12-04 |
Family
ID=41013663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000326A PE20091678A1 (es) | 2008-03-03 | 2009-03-03 | Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion-176 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20090221642A1 (es) |
| EP (1) | EP2262795A4 (es) |
| JP (1) | JP2011513394A (es) |
| KR (1) | KR20100131469A (es) |
| CN (1) | CN102015688A (es) |
| AR (1) | AR070744A1 (es) |
| AU (1) | AU2009220270A1 (es) |
| BR (1) | BRPI0908563A2 (es) |
| CA (1) | CA2717478A1 (es) |
| CL (1) | CL2009000491A1 (es) |
| MX (1) | MX2010009756A (es) |
| PE (1) | PE20091678A1 (es) |
| RU (1) | RU2010136721A (es) |
| TW (1) | TW200940056A (es) |
| WO (1) | WO2009110844A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| TW200815405A (en) * | 2006-06-09 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| US8168794B2 (en) | 2008-03-03 | 2012-05-01 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| US20110295013A1 (en) * | 2009-02-03 | 2011-12-01 | Hiroshi Iwamura | Process for preparing 1-(4-piperidinyl)benzimidazolone derivatives |
| US8362270B2 (en) * | 2010-05-11 | 2013-01-29 | Xerox Corporation | Self-assembled nanostructures |
| TW201211028A (en) * | 2010-08-10 | 2012-03-16 | Dainippon Sumitomo Pharma Co | Fused ring pyrrolidine derivatives |
| JP2015083543A (ja) * | 2012-02-14 | 2015-04-30 | 大日本住友製薬株式会社 | 新規縮環ピロリジン誘導体 |
| KR20150013548A (ko) | 2012-05-21 | 2015-02-05 | 노파르티스 아게 | 키나제 억제제로서의 신규 고리-치환된 n-피리디닐 아미드 |
| KR101811549B1 (ko) * | 2013-06-19 | 2017-12-26 | 에프. 호프만-라 로슈 아게 | 인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1221443B1 (en) * | 1999-10-13 | 2004-09-01 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| EP1515722A4 (en) * | 2002-06-17 | 2006-06-21 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| WO2007036718A2 (en) * | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
| TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| TW200815405A (en) * | 2006-06-09 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| US8119661B2 (en) * | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
-
2009
- 2009-02-25 US US12/392,293 patent/US20090221642A1/en not_active Abandoned
- 2009-03-02 JP JP2010549611A patent/JP2011513394A/ja active Pending
- 2009-03-02 MX MX2010009756A patent/MX2010009756A/es unknown
- 2009-03-02 RU RU2010136721/04A patent/RU2010136721A/ru not_active Application Discontinuation
- 2009-03-02 TW TW098106738A patent/TW200940056A/zh unknown
- 2009-03-02 CL CL2009000491A patent/CL2009000491A1/es unknown
- 2009-03-02 CN CN200980116040XA patent/CN102015688A/zh active Pending
- 2009-03-02 AU AU2009220270A patent/AU2009220270A1/en not_active Abandoned
- 2009-03-02 EP EP09716228A patent/EP2262795A4/en not_active Withdrawn
- 2009-03-02 CA CA2717478A patent/CA2717478A1/en not_active Abandoned
- 2009-03-02 KR KR1020107021981A patent/KR20100131469A/ko not_active Withdrawn
- 2009-03-02 BR BRPI0908563A patent/BRPI0908563A2/pt not_active IP Right Cessation
- 2009-03-02 WO PCT/SE2009/050224 patent/WO2009110844A1/en not_active Ceased
- 2009-03-03 AR ARP090100744A patent/AR070744A1/es unknown
- 2009-03-03 PE PE2009000326A patent/PE20091678A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100131469A (ko) | 2010-12-15 |
| MX2010009756A (es) | 2010-10-15 |
| EP2262795A1 (en) | 2010-12-22 |
| AR070744A1 (es) | 2010-04-28 |
| AU2009220270A1 (en) | 2009-09-11 |
| JP2011513394A (ja) | 2011-04-28 |
| US20090221642A1 (en) | 2009-09-03 |
| CL2009000491A1 (es) | 2010-05-14 |
| CN102015688A (zh) | 2011-04-13 |
| EP2262795A4 (en) | 2012-03-07 |
| TW200940056A (en) | 2009-10-01 |
| BRPI0908563A2 (pt) | 2017-05-23 |
| RU2010136721A (ru) | 2012-04-10 |
| WO2009110844A1 (en) | 2009-09-11 |
| CA2717478A1 (en) | 2009-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091678A1 (es) | Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion-176 | |
| AR064355A1 (es) | Herbicidas derivados de isoxazol | |
| PE20141041A1 (es) | Compuestos, metodos y formulaciones parasiticidas | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| PE20110397A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
| PE20081504A1 (es) | Compuestos de biciclocarboxiamida sustituidos | |
| AR055635A1 (es) | Uso de sulfonanilidas como herbicidas | |
| CO6321130A2 (es) | Piridinas carboxamidas como inhibidores de la 11 beta-hsd1 | |
| PE20080889A1 (es) | Aminometil-4-imidazoles | |
| AR059516A1 (es) | Derivados de isoxazolina, procesos de obtencion y composiciones herbicidas | |
| PE20080830A1 (es) | Compuestos derivados de sulfonilo que modulan el receptor cb2 | |
| PE20090896A1 (es) | Derivados de amidas como ligandos de los receptores taar1 | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20130647A1 (es) | Indoles | |
| CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
| ES2184482T3 (es) | Benzazoles, derivados del venzoxazol, el benzotiazol y el bencimidazol. | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| PE20140868A1 (es) | Antagonistas trpm8 y su uso en tratamientos | |
| DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| AR060593A1 (es) | 5-amido-2-carboxiamida-indoles | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| NI201000011A (es) | Derivados de pirimidina 934. | |
| AR076610A1 (es) | Compuestos spiro epoxidos como intermediarios | |
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| PE20081753A1 (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |